A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 31 Oct 2018 Planned End Date changed from 24 Feb 2019 to 8 Mar 2019.
- 31 Oct 2018 Planned primary completion date changed from 24 Feb 2019 to 8 Mar 2019.
- 31 Oct 2018 Status changed from recruiting to active, no longer recruiting.